Introduction

Human Herpesvirus 6 (HHV-6) is a member of the β-herpesvirus subfamily of Herpesviridae and contains a genome of approximately 160 kb encoding 97 unique genes [1]. Two variants have been identified, HHV-6A and HHV-6B, with approximately 90% nucleotide homology. While molecular genotyping has shown that infection with the HHV-6B variant is predominantly (>95%) found in Japan [2], Europe [3, 4] and the US [5], infection with the HHV-6A variant is the major endemic form in West Africa [6].

Infection with HHV-6 usually presents as a febrile illness in children within the first 3 years of life [1]. During initial HHV-6 infection in children, approximately 20% display roseola infantum, which is an illness characterized by high fever and extensive rash on the face and body [7]. Although 100% of adults are proposed to be HHV-6 infected, this virus has also been associated with several neurological conditions [8]. For example, HHV-6 infection is linked to encephalitis in children and immunosuppressed adults [1] and is the likely culprit of many unexplained cases of encephalitis [9-11]. Evidence for a pathological role of HHV-6 infection in mesial temporal lobe epilepsy has also been demonstrated as HHV-6 DNA has been detected in affected brain tissue [12, 13]. Although controversial, HHV-6 may also be involved in chronic

Original Article
No serological evidence for a role of HHV-6 infection in chronic fatigue syndrome

Peter D Burbelo1*, Ahmad Bayat1*, Jason Wagner1, Thomas B Nutman2, James N Baraniuk3, Michael J Iadarola1

1Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD; 2The Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; 3Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C. 20007-2197. *Contributed equally to this study.

Abstract: Human herpesvirus 6A (HHV-6A) and human herpesvirus 6B (HHV-6B) are associated with a variety of conditions including rash, fever, and encephalitis and may play a role in several neurological diseases. Here luciferase immunoprecipitation systems (LIPS) was used to develop HHV-6 serologic diagnostic tests using antigens encoded by the U11 gene from HHV-6A (p100) and HHV-6B (p101). Analysis of the antibody responses against Renilla luciferase fusions with different HHV-6B p101 fragments identified an antigenic fragment (amino acids 389 to 858) that demonstrated ~86% seropositivity in serum samples from healthy US blood donors. Additional experiments detected a HHV-6A antigenic fragment (amino acids 751-870) that showed ~48% antibody seropositivity in samples from Mali, Africa, a known HHV-6A endemic region. In contrast to the high levels of HHV-6A immunoreactivity seen in the African samples, testing of US blood donors with the HHV-6A p100 antigenic fragment revealed little immunoreactivity. To potentially explore the role of HHV-6 infection in human disease, a blinded cohort of controls (n=59) and chronic fatigue syndrome (CFS) patients (n=72) from the US was examined for serum antibodies. While only a few of the controls and CFS patients showed high level immunoreactivity with HHV-6A, a majority of both the controls and CFS patients showed significant immunoreactivity with HHV-6B. However, no statistically significant differences in antibody levels or frequency of HHV-6A or HHV-6B infection were detected between the controls and CFS patients. These findings highlight the utility of LIPS for exploring the seroepidemiology of HHV-6A and HHV-6B infection, but suggest that these viruses are unlikely to play a role in the pathogenesis of CFS.

Keywords: Chronic Fatigue Syndrome (CFS), Human Herpes Virus-6 (HHV6), luciferase immunoprecipitation systems (LIPS)
fatigue syndrome (CFS) and multiple sclerosis [8]. HHV-6 DNA has been found in brain lesions of multiple sclerosis patients [14, 15] and serological studies have reported elevated antibodies against HHV-6 in early stages of multiple sclerosis [16, 17]. In CFS, one study found that 70% of the patients versus 20% of the controls showed active HHV-6 replication [18]. However, two other studies found no significant association between HHV-6 infection and CFS [19, 20].

Given the potential role of HHV-6 infection in different diseases, better and more accurate methods are needed to diagnose and monitor infection. Quantitative PCR-based tests are useful for HHV-6 diagnosis and determining viral load, but serological tests such as immunofluorescence, Western blots, and ELISAs have the potential to differentiate latent from lytic infection, as well as, have the ability to detect past exposure. Unfortunately, many of the current HHV-6 ELISAs employ crude viral cell lysates which may show cross-immunoreactivity with other herpes virus proteins and are unable to distinguish between HHV-6A and HHV-6B infection. However, based on the identification of the HHV-6 U11 gene product as a diagnostic antigen [21, 22], more recent Western blotting studies have used the U11 recombinant protein, including the p101 protein of HHV-6B, to detect seropositivity in approximately 82% of healthy Japanese adults [23]. Nevertheless, the approach of using HHV-6 Western blotting is not highly quantitative and is less than optimal for high-throughput seroepidemiologic studies.

Previously, the liquid phase luciferase immunoprecipitation systems (LIPS) that employs mammalian cell-produced, recombinant Renilla luciferase fusion antigens was used for the quantitative evaluation of antibody responses to a number of different herpes viruses including HSV-1 [24], HSV-2 [24], CMV [25], EBV [26, 27], HHV-8 [28, 29], rhesus lymphocryptovirus [30] and rhesus CMV [31]. Here novel LIPS assays for measuring antibody responses against recombinant antigens from HHV-6A and HHV-6B were developed and used to study the role of HHV-6 infection in CFS.

Material and methods

Subject samples

Informed written consent was obtained from all subjects in accordance with the human experimentation guidelines of the Department of Health and Human Services and the studies were conducted according to the principles expressed in the Declaration of Helsinki. Sera were obtained from volunteers or patients under institutional review board-approved protocols at the NIH, Bethesda, MD and Georgetown University Medical Center, Washington, DC. One cohort contained serum samples (n=22) from adult blood donors from the NIH Clinical Center, NIH. Additionally, a cohort of serum samples (n=22) from Mali, Africa was studied. A third cohort, collected from Georgetown University Medical Center, Washington, DC contained both control subjects (n=59) and CFS patients (n=72), represented random samples selected from a previously published study [32]. All CFS patients fulfilled the established clinical criteria [33]. The average age of the control subjects and CFS patients was approximately 48 and 50 years, respectively. The control and CFS serum samples were analyzed for anti-HHV-6 antibodies as anonymous, de-identified blinded samples.

Generation of protein fragments for HHV-6A and HHV-6B serological testing

The mammalian Renilla luciferase expression vector, pREN2, was used to generate all plasmids. HHV-6 protein fragments were amplified by PCR with gene specific primers using genomic DNA (Advanced Biotechnologies Inc., MD). For the p101 protein of HHV-6B, six different protein fragments were generated including p101-Δ1 (aa 2-389), p101-Δ2 (aa 389-858), p101-Δ3 (aa 389-567), p101-Δ4 (aa 567-738) and p101-Δ5 (aa 738-858). In addition, four different protein fragments were generated for the p100 protein of HHV-6A including p100-Δ2 (aa 390-870), p100-Δ3 (aa 390-579), p100-Δ4 (aa 580-750), and p100-Δ5 (aa 751-870). All HHV-6 DNA fragments were subcloned down-stream of Renilla luciferase and a stop codon was inserted directly after the HHV-6 protein coding sequence. Each plasmid construct was confirmed by DNA sequencing. The details of the nucleotide and amino acid sequences for the two most informative constructs used for serological testing in our study, HHV-6A-Δ5 and HHV-6B-Δ2 have been deposited in the GenBank database with the accession numbers JX152762 and JX235339, respectively.
Fusion proteins for the different HHV-6 protein fragments were generated by transfecting Cos-1 cells with pREN2 expression vectors using X-tremeGene (Roche). Forty-eight hours later, cell lysates were prepared from the Cos1 cells by first briefly washing the cell layer with PBS. Next, lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1% Triton X-100 and 50% glycerol containing protease inhibitors) was added and the cell layer was scraped and sonicated on ice. The lysates were centrifuged twice at 13,000 x g, supernatants collected and then stored at -20°C until use. The activities of the lysates (light units, LU/ml) were next determined using a single tube luminometer (20/20 from Turner Scientific) with a coelenterazine substrate mix (Promega, Madison, WI).

LIPS analysis

Using a 96-well plate format, all LIPS assays were performed at room temperature as previously described [34]. Patient sera were first diluted 1:10 in assay buffer A (20 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1% Triton X-100) in 96-well polypropylene microtiter plates. To quantify antibody titers by LIPS, 40 μl of buffer A, 10 μl of diluted human plasma (1 μl equivalent), and 50 μl of 1 x 10^7 light units (LU) of Renilla luciferase-antigen Cos1 cell extract, diluted in buffer A, were added to each well of polypropylene plates and incubated for 1 hour at room temperature. Next, 7 μl of a 30% suspension of Ultralink protein A/G beads (Pierce Biotechnology, Rockford, IL) in PBS was added to the bottom of each well of a 96-well filter HTS plate (Millipore, Bedford, MA). The 100 μl antigen-antibody reaction mixture was then transferred to filter plates and incubated for 1 hour at room temperature on a rotary shaker. Proteins bound to the protein A/G beads were washed 10 times with buffer A and twice with PBS using a BioMek FX work station (Beckman Coulter, Fullerton, CA) with an integrated vacuum manifold. After the final wash, LU were measured in a Berthold LB 960 Centr microplate luminometer (Berthold Technologies, Bad Wildbad, Germany) using coelenterazine substrate mix (Promega, Madison, WI). All of the LU data shown represent the average of at least two independent experiments.

Statistical analysis

GraphPad Prism software (San Diego, CA) was used for data and statistical analyses. For the calculation of sensitivity and specificity, a simple statistically based cut-off value for each antigen was derived from the mean value plus 10 standard deviations of the buffer blanks. As described in the figure legends, heatmap was used in Figure 1 and 2 to signify the relative antibody levels in the samples. Results for quantitative HHV-6A and HHV-6B antibody levels between the controls and CFS patients were reported as the geometric mean ± the 95% confidence interval. Mann-Whitney U tests were used for comparison of antibody titers in different groups and the level of significance was set at P<0.05. The statistical significance of prevalence differences in HHV-6 infection were also evaluated using the Fischer’s exact test.

Results

Identification of an immunodominant p101 protein fragment of HHV-6B

Our previously published LIPS study detecting antibodies against protein fragments of the U11 tegument protein of CMV showed high diagnostic performance [25]. We hypothesized that protein fragments of the corresponding functional homolog, p101 of HHV-6B, might also be informative for serological testing. Using HHV-6B genomic DNA as a template, initially two different fragments spanning the full-length p101 protein were generated as C-terminal Renilla luciferase fusion proteins (Figure 1A). These two HHV-6B p101 constructs were expressed in Cos1 cells and the lysates were tested in LIPS assays to evaluate serum samples from 22 healthy US blood donors. The serological discriminatory potential against each of the fragments was evaluated by comparing the fold signal over buffer blanks in a heatmap format. Values greater than 5-fold were assigned a seropositive status. Using the p101-Δ1 N-terminal fragment, seven of the 22 sera showed seropositivity above the cut-off value (Figure 1B). In contrast, the p101-Δ2 protein C-terminal half of p101 was more useful and detected positive antibody responses in 84% (19/22) of the healthy blood donors (Figure 1B). The dynamic range of the antibody titers against the p101-Δ2 protein fragments in the serum samples varied by approximately 100-fold ranging from 1,119 to 135,200 LU. Based on the highly immunoreactive nature of p101-Δ2 protein fragment in 86% of the normal blood donors, three additional non-overlapping subfragments of this
region were generated and tested to explore whether they might be more diagnostically useful (Figure 1A). However, all three subfragments were less immunoreactive than the p101-Δ2 protein fragment (Figure 1B). Specifically, the p101-Δ3 fragment displayed immunoreactivity with 14 of the 22 serum samples, p101-Δ4 was immunoreactive with 16 of the 22 and the p101-Δ5 reacted with 9 of the 22 healthy blood donor samples. Further analysis revealed that the p101-Δ4 and p101-Δ2 correlated well, but the other protein fragments were less immunogenic. Collectively, these results with HHV-6-Δ2 fragment, the most useful serologically, suggest that antibodies against HHV-6B antibodies are relatively common in US human adults.

**Detection of antibodies directed against p101 of HHV-6A in African serum samples**

Due to the high prevalence of HHV-6A infection in certain geographical areas such as West Africa, immunoreactivity was also tested against the p100 protein of HHV-6A. Screening of four p100 HHV-6A protein fragments with a cohort of serum samples from Mali Africa revealed that one antigenic fragment derived from the C-terminus of p100 (designated p100-Δ5; amino acids 751-870) was the most immunoreactive (Figure 2A and data not shown). Analysis of the scatter plot revealed that 12 of the 25 samples showed antibody responses above the cut-off for the HHV-6A p101 fragment. Interestingly the HHV-6A seropositive samples in this cohort showed a bimodal antibody response. Six of the serum samples showed extremely high antibody levels over 800,000 LU, while the other 13 samples showed much lower levels of antibody ranging from 4,000 to 40,000 LU (Figure 2A). Re-testing the African samples for anti-HHV-6B antibodies with the p100-Δ2 fragment revealed that 20 of the 25 samples were seropositive, in
which several of the samples were HHV-6B sero-positive but not HHV-6A seropositive (Figure 2A and Figure 2B). Additionally, direct comparisons of the anti-HHV-6A and HHV-6B antibody responses revealed that many of the very high titer African subjects with anti-HHV-6A antibodies all showed markedly lower reactivity against the HHV-6B p101 protein fragment. These findings suggest that many of African samples are infected with HHV-6A but do not formally exclude the possibility that several of the samples are also coinfected with the HHV-6B.

Due to the observed immunoreactivity of the African samples with HHV-6A antigenic target, HHV-6A immunoreactivity was also examined with the US blood donor samples. However, little immunoreactivity was detected with the p101 HHV-6A fragment in the US samples (Figure 3). In contrast to the immunoreactivity observed against the HHV-6B p101 antigen with the US samples, only a few, weak antibody responses were found in several of the high-HHV-6B sero-positive subjects, which might represent cross-immunoreactivity between the p100 and p101 proteins. Taken together these results suggest that the Africa and the US clinical samples demonstrate markedly different variant-specific immunoreactivity which is consistent with epidemiological studies showing predominant HHV-6A
No serological evidence for a role of HHV-6 infection in CFS

Based on the previously reported role HHV-6 virus activation and/or reactivation plays in chronic fatigue syndrome [18], a blinded cohort of 131 serum samples CFS patients and control subjects were evaluated for immunoreactivity against HHV-6A and HHV-6B. Following testing and unblinding, the cohort was found to consist of 59 control blood donors (n=59) and 72 patients with CFS. As shown in Figure 4A, the HHV-6A seroprevalence rates and relative titers were not significantly different between the two groups. Using the designated cutoffs, seropositive HHV-6A antibody responses were found in 8 of 59 (13.5%) of the samples in the control group and 7 of 72 (9.7%) in the CFS group. Among the seropositive individuals, the geometric mean level of antibodies in the healthy controls and CFS were 22,767 LU (95% CI; 7,823-66,258) and 14,478 LU (95% CI; 5,044-41,551), respectively, in which no statistically significant difference in antibody levels by the Mann Whitney U test was found between the two groups. Similar analysis for HHV-6B immunoreactivity revealed that 45 of 59 (76%) of the samples in the control group and 54 of 72 (75%) in the CFS group were seropositive with no statistical difference in prevalence between them observed by the Fischer’s exact test (Figure 4B). Moreover, the geometric level of HHV-6B antibodies in the control group was 22,767 LU (95% CI; 7,823-66,258) and 14,478 LU (95% CI; 5,044-41,551) in the CFS group. Taken together these results suggest that there is no evidence for increased infection with or serum antibodies directed against HHV-6A or HHV-6B in CFS.

Discussion

Here we have used fragments of the p101 and p100 proteins of HHV-6B and HHV-6A, respectively, to develop serological tests for antibodies against these viruses. As might be expected, profiling antibody responses against multiple different HHV-6B fragments of p101 often showed overlapping immunoreactivity with the same patients. However, one of the largest p101 fragments of 320 amino acids in length showed the highest sensitivity with 86% seropositivity in the US samples and roughly matched the relative seropositivity (84%) seen by recombinant Western blotting in Japan, another HHV-6B endemic region [23]. Similarly, analysis of p100 protein of HHV-6A identified a 120 amino acid fragment that showed 48% seropositivity with the African samples. While our statistical approach of using a seropositive cut-off derived from the buffer blank (mean plus 10 standard deviations) is just an estimate, this value may underestimate the number of true seropositive samples. More detailed molecular and serological testing in parallel is needed to further define the cut-off value and explore whether there are some individuals who are seronegative for HHV-6 infection. It may be possible that the common assumption that 100% of adults are infected with HHV-6 is also incorrect. Other common herpes viruses including EBV, HSV-1 and CMV show infection prevalence’s of 95%, 50% and 45% respectively in the general population, suggesting the possibility that the true prevalence of HHV-6 infection is likely much lower than 100%. 

Figure 4. LIPS detection of antibodies to HHV-6A p100 (A) and HHV-6B p101 (B) in blood donor control subjects (n=59) and patients with chronic fatigue syndrome (n=72). Each circle or square symbol represents individual sample. The dashed line represents the cut-off level for determining seropositivity.
The p101 fragment of HHV-6B used in our study for serologic testing shared 81% amino acid identity with the corresponding HHV-6A p100 fragment. The finding of predominantly HHV-6B p101 antibodies in the US with little immunoreactivity with p100 HHV-6A is consistent with detecting potential HHV-6B variant-specific immunoreactivity that may represent both linear and conformational epitopes. Although testing of the African samples detected high levels of antibodies to both HHV-6A and HHV-6B, the reactivities seen in some of the high HHV-6A seropositive individuals were generally 4-100-fold higher than the levels of antibodies detected against p101 of HHV-6B. It is also possible that infection with the HHV-6A variant in the African samples induces more potent humoral responses than does the HHV-6B variant. While a high level of cross-reactivity was seen in our study between the p100 HHV-6A and p101 HHV-6B in the African samples, previous European and Japanese studies never tested samples from an HHV-6A endemic region [23, 35]. Moreover, while both of these previous studies examined HHV-6B and HHV-6A DNA co-positive samples, the likely order of infection with each of the HHV-6 variants was unknown. Based on the marked high prevalence of HHV-6B in Japan, Europe and in the US, it is likely that HHV-6B infection occurs before HHV-6A. Thus, it is possible that the antibody responses against the HHV-6A p100 protein are attenuated due to a phenomenon described as “original antigenic sin” [36]. In this scenario in the US, initial infection with HHV-6B and then subsequent infection by HHV-6A might result in lower titers of antibodies against the related HHV-6A p100 protein. Future studies with clinical samples DNA typed for HHV-6A and HHV-6B infection are needed to further explore antibody responses in coinfected individuals.

In conclusion, the results presented here demonstrate that LIPS produces highly robust values for studying HHV-6 serology. Unlike Western blotting there is no subjective scoring in the LIPS assay. Moreover, the defined antigens are easily applicable to high-throughput assay making large scale HHV-6 epidemiological studies feasible. We anticipate that the application of these LIPS test will be useful for studying the role of HHV-6 infection in other diseases including following transplantation and other neurological diseases.

Acknowledgments

This study was supported by the Intramural Research Program of the National Institute of Dental and Craniofacial Research, the National Institute of Allergy and Infectious Diseases, and from the Center for Neuroscience and Regenerative Medicine. Additional funding for the CFS subproject was from U.S. Public Health Service Award R01 ES015382 from the National Institute of Environmental and Health Science; and the Congressionally Directed Medical Research Program (CDMRP) Award W81XWH-07-1-0618.

Abbreviations: CFS, Chronic fatigue syndrome; HHV-6, Human herpesvirus 6; LIPS, Luciferase Immunoprecipitation Systems; LU, light units; SD, standard deviations.

Address correspondences to: Dr. James Baraniuk, Division of Rheumatology, Immunology and Allergy, Room 3004F, 3rd Floor, PHC Building, Georgetown University, 3800 Reservoir road, NW, Washington, D.C. 20007-2197. Tel (202)-687-8231; Fax (202)-687-9886; E-mail: baraniuj@gteorgetown.edu

References

[3] Aberle SW, Mandl CW, Kunz C, Popow-Kraupp T. Presence of human herpesvirus 6 variants A and B in saliva and peripheral blood mononu-
No serological evidence for a role of HHV-6 infection in CFS


No serological evidence for a role of HHV-6 infection in CFS


